Akorn to buy VersaPharm in $440 mln deal
Akorn said Friday it is buying VersaPharm for $440 million in cash. The seller is Tailwind Capital which acquired VersaPharm in 2007. Marietta, Georgia-based VersaPharm develops generic products designed to treat tuberculosis and other infectious diseases. Akorn said it plans to fund the deal through about $445 million in term loan borrowings. JPMorgan Chase Bank is providing financing. J.P. Morgan Securities provided financial advice to Akorn, while BMO Capital Markets advised VersaPharm/Tailwind.
9 May 2014•5 mins read
